Cat flea susceptibility to imidacloprid: results of a five year monitoring initiative

B Blagburn; Ian Denholm; R. Bond; R Arthur; M Dryden; J Hostetler; H Melhourn; N Mencke; P Payne; M Rust; I. Schroeder; M. Vaughn

Cat flea susceptibility to imidacloprid: results of a five year monitoring initiative

B Blagburn, Ian Denholm, R. Bond, R Arthur, M Dryden, J Hostetler, H Melhourn, N Mencke, P Payne, M Rust, I. Schroeder, M. Vaughn

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Abstract

A flea larval bioassay was developed to monitor the susceptibility of fleas (Ctenocephalides fe/is) to imidacloprid (Advantage® Bayer HealthCare). The assay was validated using both laboratory and field isolates of C. felis. Flea eggs representing different field isolates of C. felis were collected by veterinarians in 21 states in the United States (US) and in the United Kingdom (UK) and Germany. A total of 972 flea isolates were obtained from during the 5-year study period. Of the 972 isolates received, 768 contained sufficient numbers of eggs to conduct the larval bioassay. Greater than 5% survival occurred for only 6 of the 768 field isolates that were evaluated. Further evaluation and analysis of these
isolates demonstrated that they were not significantly different in their susceptibility to imidacloprid from the reference strains field isolates used to develop the assay. Also, at this point there do not appear to be any differences in susceptibility to imidacloprid of cat flea field isolates from the US, the UK and
Germany. Collections of field flea isolates will continue in attempt to detect and document any change in the susceptibility of field flea populations to imidacloprid.

Original language	English
Title of host publication	Proceedings of the 2006 Meeting of the American Association of Veterinary Parasitologists
Publication status	Published - 2006
Event	51st Annual Meeting of the American Association of Veterinary Parasitologistss - Sheraton Waikiki Hotel, Honolulu, United States Duration: 15 Jul 2006 → 18 Jul 2006

Conference

Conference	51st Annual Meeting of the American Association of Veterinary Parasitologistss
Country/Territory	United States
City	Honolulu
Period	15/07/06 → 18/07/06

Cite this

@inproceedings{ff455e4544ed4953ae28575c34b57cc8,

title = "Cat flea susceptibility to imidacloprid: results of a five year monitoring initiative",

abstract = "A flea larval bioassay was developed to monitor the susceptibility of fleas (Ctenocephalides fe/is) to imidacloprid (Advantage{\textregistered} Bayer HealthCare). The assay was validated using both laboratory and field isolates of C. felis. Flea eggs representing different field isolates of C. felis were collected by veterinarians in 21 states in the United States (US) and in the United Kingdom (UK) and Germany. A total of 972 flea isolates were obtained from during the 5-year study period. Of the 972 isolates received, 768 contained sufficient numbers of eggs to conduct the larval bioassay. Greater than 5% survival occurred for only 6 of the 768 field isolates that were evaluated. Further evaluation and analysis of theseisolates demonstrated that they were not significantly different in their susceptibility to imidacloprid from the reference strains field isolates used to develop the assay. Also, at this point there do not appear to be any differences in susceptibility to imidacloprid of cat flea field isolates from the US, the UK andGermany. Collections of field flea isolates will continue in attempt to detect and document any change in the susceptibility of field flea populations to imidacloprid.",

author = "B Blagburn and Ian Denholm and R. Bond and R Arthur and M Dryden and J Hostetler and H Melhourn and N Mencke and P Payne and M Rust and I. Schroeder and M. Vaughn",

year = "2006",

language = "English",

booktitle = "Proceedings of the 2006 Meeting of the American Association of Veterinary Parasitologists",

note = "51st Annual Meeting of the American Association of Veterinary Parasitologistss ; Conference date: 15-07-2006 Through 18-07-2006",

}

Blagburn, B, Denholm, I, Bond, R, Arthur, R, Dryden, M, Hostetler, J, Melhourn, H, Mencke, N, Payne, P, Rust, M, Schroeder, I & Vaughn, M 2006, Cat flea susceptibility to imidacloprid: results of a five year monitoring initiative. in Proceedings of the 2006 Meeting of the American Association of Veterinary Parasitologists. 51st Annual Meeting of the American Association of Veterinary Parasitologistss, Honolulu, United States, 15/07/06.

TY - GEN

T1 - Cat flea susceptibility to imidacloprid: results of a five year monitoring initiative

AU - Blagburn, B

AU - Denholm, Ian

AU - Bond, R.

AU - Arthur, R

AU - Dryden, M

AU - Hostetler, J

AU - Melhourn, H

AU - Mencke, N

AU - Payne, P

AU - Rust, M

AU - Schroeder, I.

AU - Vaughn, M.

PY - 2006

Y1 - 2006

N2 - A flea larval bioassay was developed to monitor the susceptibility of fleas (Ctenocephalides fe/is) to imidacloprid (Advantage® Bayer HealthCare). The assay was validated using both laboratory and field isolates of C. felis. Flea eggs representing different field isolates of C. felis were collected by veterinarians in 21 states in the United States (US) and in the United Kingdom (UK) and Germany. A total of 972 flea isolates were obtained from during the 5-year study period. Of the 972 isolates received, 768 contained sufficient numbers of eggs to conduct the larval bioassay. Greater than 5% survival occurred for only 6 of the 768 field isolates that were evaluated. Further evaluation and analysis of theseisolates demonstrated that they were not significantly different in their susceptibility to imidacloprid from the reference strains field isolates used to develop the assay. Also, at this point there do not appear to be any differences in susceptibility to imidacloprid of cat flea field isolates from the US, the UK andGermany. Collections of field flea isolates will continue in attempt to detect and document any change in the susceptibility of field flea populations to imidacloprid.

AB - A flea larval bioassay was developed to monitor the susceptibility of fleas (Ctenocephalides fe/is) to imidacloprid (Advantage® Bayer HealthCare). The assay was validated using both laboratory and field isolates of C. felis. Flea eggs representing different field isolates of C. felis were collected by veterinarians in 21 states in the United States (US) and in the United Kingdom (UK) and Germany. A total of 972 flea isolates were obtained from during the 5-year study period. Of the 972 isolates received, 768 contained sufficient numbers of eggs to conduct the larval bioassay. Greater than 5% survival occurred for only 6 of the 768 field isolates that were evaluated. Further evaluation and analysis of theseisolates demonstrated that they were not significantly different in their susceptibility to imidacloprid from the reference strains field isolates used to develop the assay. Also, at this point there do not appear to be any differences in susceptibility to imidacloprid of cat flea field isolates from the US, the UK andGermany. Collections of field flea isolates will continue in attempt to detect and document any change in the susceptibility of field flea populations to imidacloprid.

M3 - Conference contribution

BT - Proceedings of the 2006 Meeting of the American Association of Veterinary Parasitologists

T2 - 51st Annual Meeting of the American Association of Veterinary Parasitologistss

Y2 - 15 July 2006 through 18 July 2006

ER -

Cat flea susceptibility to imidacloprid: results of a five year monitoring initiative

Abstract

Conference

Fingerprint

Cite this